Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?
Autor: | A. Muñoz Martín, I. García-Escobar, J. Muñoz Langa, C. Beato-Zambrano, E Brozos Vázquez, D. Gutiérrez-Abad, B. Obispo Portero |
---|---|
Rok vydání: | 2018 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty Vitamin K medicine.drug_class Brain tumor Low molecular weight heparin 030204 cardiovascular system & hematology medicine.disease_cause 03 medical and health sciences 0302 clinical medicine Neoplasms Internal medicine medicine Humans Clinical Trials as Topic Heparin business.industry Incidence (epidemiology) Anticoagulants Cancer Venous Thromboembolism General Medicine Heparin Low-Molecular-Weight medicine.disease Clinical trial Anticoagulant therapy 030220 oncology & carcinogenesis Carcinogenesis business medicine.drug |
Zdroj: | Clinical and Translational Oncology. 20:1097-1108 |
ISSN: | 1699-3055 1699-048X |
DOI: | 10.1007/s12094-018-1835-2 |
Popis: | The association between venous thromboembolism (VTE) and cancer has been recognized for more than 100 years. Numerous studies have been performed to investigate strategies to decrease VTE incidence and to establish whether treating VTE impacts cancer progression and overall survival. Accordingly, it is important to understand the role of the hemostatic system in tumorigenesis and progression, as there is abundant evidence associating it with cell survival and proliferation, tumor angiogenesis, invasion, and dissemination, and metastasis formation. In attempts to further the scientific evidence, several studies examine survival benefits in cancer patients treated with anticoagulant therapy, specifically treatment with vitamin K antagonists, unfractionated heparin, and low-molecular-weight heparin. Several studies and meta-analyses have been conducted with a special focus on brain tumors. However, no definitive conclusions have been obtained, and more well-designed clinical trials are needed. |
Databáze: | OpenAIRE |
Externí odkaz: |